Project Grant R44HL180181
Award Date 9/15/25
Completion Date 8/31/28
Dollars Obligated $508K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award of $760,374 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research by National Jewish Health to develop predictive molecular signatures for diagnosing sarcoidosis and identifying patients at risk of disease progression. The project will integrate single nucleotide polymorphisms, gene expression, and plasma metabolomics/lipidomics data using advanced machine learning to identify potential biomarkers....
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $778,266 to the Oklahoma Medical Research Foundation (OMRF) to conduct comprehensive research on sarcoidosis. The key objectives are to: Distinguish sarcoidosis patients from healthy and other immune-mediated disease controls using high-throughput plasma proteomics on over 2,000 participants. Identify biomarkers to distinguish sarcoidosis patients with...
- This federal Project Grant award for $300,000.00 was provided by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The award was granted to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to support the research project "INNATE LYMPHOID CELLS AND TERTIARY LYMPHOID STRUCTURES IN SARCOIDOSIS". The project aims to advance...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $173,480.00 to the University of Illinois to elucidate the mechanisms through which circulating CD14+ monocytes drive the inflammatory-fibrotic axis of advanced pulmonary sarcoidosis-related fibrosis (APSF). The award aims to use single-cell RNA sequencing and surface protein indexing to identify key regulators and signaling pathways within...
- The University of Washington received a $663,578 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 15, 2025 through May 31, 2029, supports research to better diagnose and understand cardiac sarcoidosis, a form of inflammatory cardiomyopathy. The project aims to "perform 'deep phenotyping' with genetic testing, PET imaging, metabolomic studies, and voltage-guided endomyocardial...
- The National Heart, Lung, and Blood Institute awarded a $249,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to National Jewish Health to identify common and distinct metabolic and proteomic pathways associated with inflammation and fibrosis in pulmonary sarcoidosis. The 2-year project aims to use plasma specimens to characterize metabolic and proteomic profiles that differentiate fibrotic and non-fibrotic pulmonary sarcoidosis phenotypes and endotypes. This...
- This federal Project Grant award of $304,993 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Immunowork LLC, located in Monrovia, CA. The award supports a research project to quantify peripheral blood antigen-specific memory B cells as a new biomarker in patients with PLA2R-associated membranous nephropathy, a common form of nephrotic syndrome. The goal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Pearl Diagnostics, Inc., a Baltimore-based small business. The grant supports the final integration and clinical testing required for FDA clearance of Pearl Diagnostics' lateral flow device (LFD) - a rapid, point-of-care urine test to diagnose invasive aspergillosis, an infection recently named a "critical" public...
- This $356,500 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of chemically modified DNA aptamers for improved sepsis diagnosis. The grantee, Aptus Biosciences LLC, is a minority-owned small business specializing in advanced diagnostic research and development, with a focus on innovative aptamer-based technologies. The project aims to create rapid, affordable,...
- This $743,651 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to validate the use of plasma cell-free RNA (cfRNA) as a biomarker for the diagnosis of tuberculosis (TB) and monitoring of treatment. The grant will support the validation of cfRNA signatures in a large patient cohort of 1,378 adults across five countries, and the comparison of cfRNA diagnostic accuracy against...